(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...

Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...

Gilead Sciences (NasdaqGS:GILD) recently achieved FDA approval for Yeztugo, a significant step in HIV prevention as the first ...

FOSTER CITY, Calif., May 31, 2025--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced Trodelvy ® (sacituzumab govitecan-hziy) plus Keytruda ...

Trodelvy (sacituzumab govitecan-hziy) is a prescription drug used to treat breast cancer in certain situations. Trodelvy comes as a powder that’s made into a liquid mixture. A healthcare ...

Second Positive Phase 3 Trial in First-line Metastatic TNBC Where Trodelvy Has Demonstrated a Clinically Meaningful Benefit Versus Standard of Care Chemotherapy – – Trodelvy Has the Potential ...

Image Source: Zacks Investment Research More on GILD’s Trodelvy Trodelvy is a first-in-class Trop-2-directed antibody-drug conjugate. The ASCENT-03 study is a global, open-label, randomized ...

Trodelvy (sacituzumab govitecan-hziy) is a brand-name IV infusion prescribed for certain types of breast cancer in adults. As with other drugs, Trodelvy can cause side effects, such as diarrhea ...

Trodelvy plus Keytruda improved progression-free survival in PD-L1–positive, advanced TNBC, reducing disease progression or death risk by 35% compared to chemotherapy plus Keytruda. The phase 3 ASCENT ...

Trodelvy plus Keytruda significantly improves progression-free survival in metastatic triple-negative breast cancer expressing PD-L1 compared to Keytruda and chemotherapy. The safety profile of the ...